SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com/.
Allos Therapeutics (Nasdaq: ALTH) $7.86. Announced Wednesday after market close that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
PTCL comprises a biologically diverse group of aggressive blood cancers that has a worse prognosis than most other types of lymphoma, including B-cell lymphoma. If approved, FOLOTYN would be the first drug approved by the FDA for the treatment of relapsed or refractory PTCL.
What They Do: Allos Therapeutics is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics.
Gentiva Health Services (Nasdaq: GTIV) $21.61. Announced Wednesday after market close that it has completed its acquisition of Rush Home Care, Inc. (d/b/a Magna Home Health), a part of the Rush Health System, located in central Mississippi and west central Alabama. The purchase was funded from Gentiva's existing cash reserves.
"We extend a warm welcome to all Magna Home Health employees and anticipate a smooth transition as we enter seven new counties requiring a certificate of need to participate in the delivery of home health services," said Gentiva CEO and President Tony Strange. "We also look forward to the possibility of bringing our groundbreaking specialty home health programs and other Gentiva services to these areas as yet another way to differentiate us from the competition and build strong relationships with physicians and payers."
The acquisition is not expected to have a material impact on Gentiva's financial position or results of operations in 2009.
Gentiva Health Services is currently a focus stock at www.SmallCapReview.com.
What They Do: Gentiva Health Services, Inc. is a leading provider of comprehensive home health services, delivering innovative, high quality care to patients across the United States. Gentiva is a single source for skilled nursing; physical, occupational, speech and neurorehabilitation services; hospice services; social work; nutrition; disease management education; help with daily living activities; respiratory therapy and home medical equipment; infusion therapy services; and other therapies and services.
Dainippon Sumitomo Pharma and Sepracor (Nasdaq: SEPR) $22.80. Announced Wednesday after market close that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer. The tender offer price represents a 48.0% premium to Sepracor’s average stock price over the last six month period ending on September 1, and a 27.6% premium over the closing price of Sepracor’s common stock on September 1, 2009. The transaction was unanimously approved by the Boards of Directors of both companies. Upon completion of the acquisition, Sepracor will become a wholly owned subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc., a wholly owned U.S. subsidiary of DSP, and will continue its operations based in Marlborough, Massachusetts and in Canada. Sepracor will retain its name, branding and intellectual property rights and continue to operate as Sepracor.
What They Do: Sepracor is a fully integrated specialty pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs.
SIGA Technologies (Nasdaq: SIGA) $6.72. Today announced that its common stock listing will transfer from the NASDAQ Capital Market to the NASDAQ Global Market. The transfer will be effective at the opening of business on Thursday, September 3, 2009 and the Company's common stock will continue to trade under the symbol "SIGA".
Commenting on the move, Dr. Eric Rose, SIGA's Chief Executive Officer, said, "The transfer of SIGA's stock to the NASDAQ Global Market reflects SIGA's growth over the past year. We believe that the transfer to the Global Market will provide our investors with expanded liquidity for their SIGA stock."
What They Do: SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
